Xilio Therapeutic announced initial clinical data from its ongoing Phase 1C clinical trial evaluating vilastobart, a tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4, in combination with atezolizumab in patients with advanced solid tumors. The data will be presented in a late-breaker poster presentation on November 8, 2024, at the Society for Immunotherapy of Cancer, SITC, 39th Annual Meeting taking place in Houston, Texas.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XLO: